NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on February 6, 2020 ...
If you're interested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), then you might want to consider its beta (a...
Q1 2020 Enanta Pharmaceuticals Inc Earnings Call
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Enanta Pharmaceuticals (ENTA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Q2 2020 Enanta Pharmaceuticals Inc Earnings Call
Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 58.90% and -9.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Enanta’s Hepatitis C Virus (HCV) Collaboration Partner AbbVie Receives Marketing Authorization from the European Commission to Shorten MAVIRET®
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 10.17% and -11.37%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic
On the call today is Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team. Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from these statements.
Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis
Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2020